Efficacy and safety of seladelpar in patients with primary biliary cholangitis and alkaline phosphatase levels between 1 and 1.67 × upper limit of normal: interim results from the open-label ASSURE study

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Efficacy and safety of seladelpar in patients with primary biliary cholangitis and alkaline phosphatase levels between 1 and 1.67 × upper limit of normal: interim results from the open-label ASSURE study

	EASL 2026 May 26-30 Barcelona Cynthia Levy1,2,